Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics and outcome, cohort 1

From: Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Patient Response Characteristics (m1/f2; age (y3)) Phototype Histological type BRAF Status (wt5/mut6) Checkpoint inhibitor therapy Number of involved organs Metastasis ECOG9 Performance status Tumor Response at first CT scan10
1 Responders m, 70 2 SSM4 mut anti-PD17 2 Lung, Lymph nodes 0 PR
2 m, 70 3 SSM wt anti-PD1 3 Soft tissue, Bone, Liver 0–1 SD*
3 f, 78 2 SSM wt anti-PD1 + anti-CTLA48 3 Soft tissue, Lymph nodes, Lung 0 PR
4 m, 63 3 SSM wt anti-PD1 1 Lung 0 PR
5 m, 52 3 SSM mut anti-PD1 + anti-CTLA4 4 Mesenterium, Peritoneum, Retroperitoneum, Brain 0 SD*
6 m, 86 3 nodular wt anti-PD1 2 Bone, Lung 0 PR
7 f, 66 2 nodular mut anti-CTLA4 5 Lymph nodes, Lung, Soft tissue, Suprarenal gland, Stomach 0 PR
8 f, 81 2 nodular wt anti-PD1 5 Lymph node, Soft tissue, Lung, Bone, Liver 0 PR
9 f, 66 2 nodular wt anti-PD1 3 Soft tissue, Lymph nodes, Brain 0 PR
10 m, 78 2 nodular wt anti-PD1 3 Soft Tissue, Lymph nodes, Lung 0 CR
11 f, 61 1 uveal wt anti-PD1 1 Bone 0 PR
12 m, 66 2 mucosal wt anti-PD1 6 Soft tissue, Lung, Pankreas, Small pelvis, Liver, Bone 0 PR
13 Non-Responders m, 62 2 SSM wt anti-PD1 4 Suprarenal gland, Lung, Lymph node, Brain 0 SD
14 f, 56 2 SSM mut anti-PD1 + anti-CTLA4 5 Lung, Lymph node, Soft tissue, Liver, Stomach 1 PD
15 f, 87 3 nodular mut anti-PD1 5 Lung, Lymph node, Liver, Bone, Brain 1 SD
16 f, 71 2 uveal wt anti-CTLA4 3 Lung, Liver, Brain 0 PD
17 f, 71 2 uveal wt anti-PD1 2 Liver, Lymph node 0 SD
18 f, 87 2 mucuosal wt anti-PD1 1 Soft tissue 1 PD
19 f, 71 2 unknown, amelanotic wt anti-PD1 3 Lung, Lymph node, Suprarenal gland 0 SD
20 m, 72 3 unknown wt anti-PD1 7 Lung, Liver, Lymph node, Suprarenal gland, Pankreas, Bone, Eye muscle 0 PD
  1. * pseudoprogression, 1 male, 2 female, 3 years, 4 superficial spreading melanoma, 5 wild type, 6 V600E mutation, 7 anti-programmed-cell-death protein-1, 8anti-cytotoxic-T-lymphocyte-associated-protein-4, 9Eastern Cooperative Oncology Group,10 CR Complete Remission, PR Partial Remission, SD Stable Disease, PD Progressive Disease